Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies

The number of elderly patients with cancer has increased due to aging of the population. However, safety of programmed cell death-1 (PD-1) or programed cell death ligand 1 (PD-L1) inhibitors in elderly patients remains controversial, and limited information exists in frail patients. The present stud...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Sakakida, Tomoki, Ishikawa, Takeshi, Uchino, Junji, Tabuchi, Yusuke, Komori, Satoshi, Asai, Jun, Arai, Akihito, Tsunezuka, Hiroaki, Kosuga, Toshiyuki, Konishi, Hirotaka, Hongo, Fumiya, Inoue, Masayoshi, Hirano, Shigeru, Ukimura, Osamu, Taguchi, Tetsuya, Takayama, Koichi, Itoh, Yoshito
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2020
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7406883/
https://ncbi.nlm.nih.gov/pubmed/32774487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11875
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars